EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Inactivating conditions of therapeutic mycobacteriophages

Andrew Wiggins, Umar N Chaudhry, Fabiana Bisaro, Addison Lueck, Alan A Schmalstig, Graham F Hatfull iD, David B Hill iD, Miriam Braunstein iD

Microbiology Spectrum · 2026

DOI: 10.1128/spectrum.02655-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2026. Verfasst von Andrew Wiggins und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA. Hauptthemen laut MEDLINE: Mycobacteriophages, Phage Therapy, Mycobacterium Infections, Nontuberculous, Nontuberculous Mycobacteria. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, National Science Foundation, Emily's Entourage.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

There is a need for new therapies to treat drug-resistant nontuberculous mycobacteria (NTM) disease. Bacteriophages (phages), which are viruses that infect and kill bacteria, are actively being explored as an alternative approach for treating mycobacterial diseases. Several compassionate-use cases of phage therapy for drug-resistant NTM infections exhibit favorable outcomes. To further the development of phage therapy, it is important to recognize and avoid conditions that negatively impact phage activity during phage production, storage, formulation, or treatment. Conversely, there is a need to inactivate free phages in certain preclinical phage therapy experiments. In this study, we investigated three mycobacteriophages BPsΔ 33 HTH-HRM10, Muddy, and ZoeJΔ 45 from compassionate-use NTM treatment cases for their sensitivity to a variety of conditions that included temperature, acid pH, detergents, mucus, and phage inactivating buffers. Several conditions resulted in dramatic and rapid reductions in the level of active phage, while others had no effect. We also observed different sensitivities between the phages. The results provide valuable information to support further investigation and development of these phages as therapeutics. IMPORTANCE Bacteriophages (phages) offer a promising alternative therapy for treating drug-resistant mycobacterial infections. For the successful implementation of phage therapy, it is important to recognize conditions that inactivate the phages. Here, we studied three mycobacteriophages from recent compassionate-use phage therapy cases for their sensitivity to a range of conditions that may be encountered in production, storage, formulation, or treatment. The results demonstrate sensitivity to some conditions and tolerance to others, and they additionally reveal phage-specific differences in sensitivities, highlighting the need for direct evaluation of individual therapeutic phages during development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MycobacteriophagesPhage TherapyMycobacterium Infections, NontuberculousNontuberculous MycobacteriaVirus InactivationHydrogen-Ion ConcentrationTemperatureHumans

Stichwörter der Autor:innen

bacteriophagemycobacteriophagenontuberculous mycobacteria

Autor:innen und Institutionen

  • Department of Microbiology, Immunology, and Pathology, Mycobacteria Research Laboratories, Colorado State University, Fort Collins, Colorado, USA.
  • Department of Microbiology and Immunology, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
  • Cell and Molecular Biology Program, Colorado State University, Fort Collins, Colorado, USA.
  • Department of Biological Sciences, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
  • Marsico Lung Institute and Lampe Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

ORCID-Profile: Graham F Hatfull, David B Hill, Miriam Braunstein

Förderung

  • National Institute of Allergy and Infectious Diseases
  • National Science Foundation
  • Emily's Entourage
  • NIDDK NIH HHS
  • NIAID NIH HHS
  • Cystic Fibrosis Foundation
  • NIGMS NIH HHS
  • Howard Hughes Medical Institute

Zitieren

APA

Wiggins, A., Chaudhry, U. N., Bisaro, F., Lueck, A., Schmalstig, A. A., Hatfull, G. F., Hill, D. B., & Braunstein, M. (2026). Inactivating conditions of therapeutic mycobacteriophages. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02655-25

Vancouver

Wiggins A, Chaudhry UN, Bisaro F, Lueck A, Schmalstig AA, Hatfull GF, et al. Inactivating conditions of therapeutic mycobacteriophages. Microbiology Spectrum. 2026. doi:10.1128/spectrum.02655-25

BibTeX
@article{Wiggins2026,
  author = {Wiggins, Andrew and Chaudhry, Umar N and Bisaro, Fabiana and Lueck, Addison and Schmalstig, Alan A and Hatfull, Graham F and Hill, David B and Braunstein, Miriam},
  title = {Inactivating conditions of therapeutic mycobacteriophages},
  journal = {Microbiology Spectrum},
  year = {2026},
  doi = {10.1128/spectrum.02655-25}
}
Kostenlos starten →